Moderna said last week that the vaccine candidate, the first to be tested in the United States, produced protective antibodies in a small group of healthy volunteers, offering a glimmer of hope for a vaccine among the most advanced in development.
The extended agreement with the supplier of pharmaceutical ingredients CordenPharma will be effective immediately to help meet rising demand in the coming months, Moderna said in a statement.
“This expansion will increase the supply of lipid adjuvants used to make our mRNA products,” said Modern Technical Operations and Quality Manager, Juan Andres.
Moderna plans to deliver millions of doses per day. Month by 2020 and tens of millions per month by 2021 if the vaccine proves to be successful.
There are currently no approved treatments or vaccines against COVID-19, and experts predict that a safe and effective vaccine can take 12 to 18 months from the onset of development, which in the case of Moderna was in January.
(Reporting by Shubham Kalia in Bengaluru; Editing by David Clarke)